This is from Seeking Alpha
I am doing it in parts---
Risky Enzolytics Inc. Delivered Triple-Digit Stock Returns
Jan. 27, 2021 3:23 PM ETEnzolytics Inc. (ENZC)IMMB1 Comment
Summary
Enzolytics, Inc. owns licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS.
The company's treatment appears to be different from other treatments. Enzolytics Inc. claims to be offering a product with zero toxicity issues, minor side effects, and cost savings.
According to their website, they have tested 31 patients. Besides, they are about to acquire a new laboratory, which will most likely be operational in June 2021.
Enzolytics Inc. targets a market that could be close to $37 billion in 2027. That's a large market size. However, numerous companies are already selling HIV drugs. The competition in the market is significant.
Enzolytics Inc. may need to test hundreds of patients. The process will also take a lot of time and financial resources. Shareholders need to understand well that they may have to wait many years until Enzolytics Inc. can report sales.
Enzolytics, Inc. (OTCPK:ENZC) has delivered massive stock returns in 2020 and 2021. The current market capitalization is larger than $600 million. In my opinion, investors need to remain cautious. The HIV drug market is extremely competitive. Even if the company's drug is approved, sales may be lower than expected. In addition, the company will most likely need financing for the construction of its laboratory in Europe. If ENZC sells equity, the share price may decline.
Business Model
Founded in 2004, Enzolytics, Inc. owns licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS.
Still at a pre-revenue stage, Enzolytics intends to commercialize the rights for the treatment of Hepatitis C.
IPF is a peptide molecule that has a strong affinity to bind with the HIV virus' peptide components identified as gp41 and gp120 antigens, rendering them as super antigens, and taking away from them their stealthiness and their capability to destroy the immune system.
In addition to this mechanism of action, IPF will also enhance and upgrade the immune system components and criteria, as such resulting in a double impact approach of both behaving as a novel fusion inhibition treatment as well as an immuno-modulator. Source: Annual Report
The company's treatment appears to be different from other treatments. Enzolytics Inc. claims to be offering a product with zero toxicity issues, minor side effects, and cost savings.
Continued
